Back to results
US 8,686,184 B2Granted
Neprilysin inhibitors
AssigneeTheravance, Inc.
InventorsMelissa Fleury, Roland Gendron, Adam D. Hughes, Jane Schmidt
Life of this patent
Estimating the term…
Abstract
In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, a, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
Claims25
A compound of formula I:
- where:
- R1 is —OR10 or —NR60R70;
- R2 is H or —OR20;
- R3 is selected from Cl, F, —CH3, and —CF3;
- a is 0 or an integer from 1 to 3;
- R4 is selected from —C1-6alkyl;
- —C3-7cycloalkyl;
- —C0-2alkylene-COOR40;
- —NR41R42;
- —NHC(O)O—C1-6alkyl;
- —NHC(O)R43;
- —NHC(O)NH—R44;
- phenyl substituted with one or two groups independently selected from halo, —O—C1-6alkyl, —C0-1alkylene-COOR40, —SO2NH2, —C(O)NR41R42, and tetrazole;
- and —C0-2alkylene-C1-9heteroaryl or a partially unsaturated —C0-2alkylene-C3-5heterocycle both optionally substituted with 1-3 groups independently selected from halo, —OH, ═O, —CHO, —C1-6alkyl, —CF3, and —COOR40;
- R5 is selected from H, halo, —OH, —C1-6alkyl, —O—C1-6alkyl, phenyl, and morpholine;
- R6 is H or halo;
- R10 and R40 are independently selected from H, —C1-6alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R13, —C1-6alkylene-NR14R15, —C1-6alkylene-C(O)R17, —C0-6alkylenemorpholine, —C1-6alkylene-SO2—C1-6alkyl,
- R13 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR14R15, and —CH(NH2)CH2COOCH3;
- R14 and R15 are independently selected from H, —C1-6alkyl, and benzyl, or R14 and R15 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2O(CH2)2—;
- R16 is —C1-6alkyl or —C0-6alkylene-C6-10aryl;
- R17 is selected from —O—C1-6alkyl, —O-benzyl, and —NR14R15;
- R20 is H or is taken together with R10 to form —CR21R22— or is taken together with R60 to form —C(O)—;
- R21 and R22 are independently selected from H, —C1-6alkyl, and —O—C3-7cycloalkyl, or R21 and R22 are taken together to form ═O;
- R43 is selected from —C1-6alkyl, —C1-3alkylene-COOR40, phenyl, and pyridine;
- R44 is selected from —C1-6alkyl, —C1-6alkylene-COOR40, phenyl, and thiophene-COOR40, where thiophene is optionally substituted with CH3;
- R60 is selected from H, —OH, —OC(O)R61, —CH2COOH, —O-benzyl, pyridyl, and —OC(S)NR62R63;
- R61 is selected from H, —C1-6alkyl, —C6-10aryl, —OCH2—C6-10aryl, —CH2O—C6-10aryl, and —NR62R63;
- R70 is selected from H, —C1-6alkyl, and —C(O)R71;
- R71 is selected from H, —C1-6alkyl, —C3-7cycloalkyl, —C6-10aryl, and —C1-9heteroaryl;
- R41, R42, R62, and R63 are independently H or —C1-4alkyl;
- or a pharmaceutically acceptable salt thereof.
28 more elements
Dependencies are inferred from the claim text.